The U.S. market for Rx-to-OTC Switches encompasses a wide variety of products that have been determined safe and effective as over-the-counter products, once only available by prescription. This report represents the six time that Kalorama Information has analyzed the market for drugs with switched ingredients in detail. The market is fueled by several factors including an aging population; steady to increased incidences of conditions and diseases; new drug classes switched to OTC; product demand; economic conditions and several other factors.
The U.S. Market for Rx-to-OTC Switches focuses on several treatment segments in which Rx-to-OTC switches are available. These include:
The report includes statistical information for conditions and diseases affecting the U.S. population, including detail discussions, tables and figures. Each segment provides an overview, descriptions of products on the market, market estimates and forecasts, and competitive analysis of leading providers. In addition to above-mentioned information, the report includes current issues and trends affecting the industry and identifies trends that may arise in the future.
All product areas contribute to the growth and development of the OTC market; however, new product development and additional regulatory review and approval of new OTC drug classifications, specifically in areas such as allergy treatments, cholesterol-reducing drugs, urinary disorders treatments and hormones treatments are expected to make the most impact.
There are several companies that compete heavily in this market and use the Rx-to-OTC switch as a major part of their life-cycle management arsenal. Companies involved in the Rx-to-OTC switched market include brand, generic, and private label manufacturers. Competition will likely continue to be moderate in the OTC market, especially with the patent expiration of key products nearing. Consolidation remains a major factor in this market. Most major players have made a significant acquisition or formed a strategic alliance to increase revenues and drive growth. Product innovation, line extensions and strong promotional support are a few of the top strategies for growth in this industry.
Leading competitors offering key brand products are provided in this report. These companies include:
All market data pertains to the U.S. market at the manufacturers’ level. The base year for data was 2012. Historical data are provided for 2007 through 2011, with forecast data provided for 2013 through 2017. Compound annual growth rates (CAGRs) are provided for the 2007-2012, 2012-2017 and 2007-2017 periods for each industry segment covered."
Related Reports:The U.S. Market for Urgent Care Centers
Mar 22, 2013 - KLI5003148 - $2,500.00
Retail Clinics: Consumer Attitudes Results of the 2013 Kalorama Survey
Mar 22, 2013 - KLI5007914 - $995.00
The World Market for Over The Counter (OTC) Drugs
May 7, 2012 - KLI3874091 - $3,995.00
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
Mar 1, 2012 - KLI6801442 - $3,995.00
World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections)
Feb 1, 2012 - KLI6772957 - $3,800.00
The World Market for Prescription Arthritis Treatments (NSAIDs, DMARDs, BRMs and Immunosuppressants)
Nov 1, 2011 - KLI6665486 - $2,995.00
The Market for Rx to OTC Switches, 5th Editiion
Feb 1, 2011 - KLI6065752 - $3,500.00
The Worldwide Over-the-Counter (OTC) Drug Market
May 1, 2010 - KLI2661910 - $3,995.00
The Worldwide Market for Prescription Dermatological Drugs, 7th Edition
Apr 1, 2010 - KLI2616119 - $3,900.00
The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets
Oct 1, 2009 - KLI2384194 - $995.00
Questions?Contact a research specialist >
Most Popular ResearchWhy Epigenomics May Be a Game-Changer in Diagnostics and Pharmaceuticals World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas) Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline) Vaccines 2012-16 World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives